Replies to post #68360 on Biotech Values

[HobGlobulin]

RE: Cook-AVII Program

I believe you are recalling the AVII collaboration with Medtronic which fizzled out in 2003. The Cook partnership began in 2006.

This link has some background on the partnership and Resten-NG (AVI-4126), which Cook has abandoned for AVI-5126:

http://www.antivirals.com/pr/pr311.php

>> AVI licensed its vascular disease program to the Cook Group Inc. (Cook) in March 2006 for device delivery of the NeuGene® antisense drug AVI–4126, while the company is focusing internal development on coronary artery bypass graft (CABG) using AVI–5126. <<

>By the way, what ever happened to Resten-NG?<

An entire chapter in the book Biotech Fiascos will be devoted to answering this. (Just kidding.) I would give the details, but I am suffering from PTASD (Post-Traumatic AVII-Shareholder Disorder.)